Vaccines (Jun 2022)
Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Covishield<sup>TM</sup>) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021
- Sharan Murali,
- Manikandanesan Sakthivel,
- Kamaraj Pattabi,
- Vettrichelvan Venkatasamy,
- Jeromie Wesley Vivian Thangaraj,
- Anita Shete,
- Alby John Varghese,
- Jaganathan Arjun,
- Chethrapilly Purushothaman Girish Kumar,
- Pragya D Yadav,
- Rima Sahay,
- Triparna Majumdar,
- Manisha Dudhmal,
- Azhagendran Sivalingam,
- Sudha Rani Dhanapal,
- Augustine Durai Samy,
- Vijayaprabha Radhakrishnan,
- Murali Mohan Muni Krishnaiah,
- Suresh Arunachalam,
- Punita Muni Krishna Gandhi,
- Elavarasu Govindasamy,
- Prabhakaran Chinnappan,
- Dhana Priya Vadhani Sekar,
- Prakash Marappan,
- Ezhil Pounraj,
- Parasuraman Ganeshkumar,
- Murugesan Jagadeesan,
- Manish Narnaware,
- Gagandeep Singh Bedi,
- Prabhdeep Kaur,
- Manoj Murhekar
Affiliations
- Sharan Murali
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Manikandanesan Sakthivel
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Kamaraj Pattabi
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Vettrichelvan Venkatasamy
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Jeromie Wesley Vivian Thangaraj
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Anita Shete
- Indian Council of Medical Research—National Institute of Virology, Pune 411001, India
- Alby John Varghese
- Greater Chennai Corporation, Ripon Building, Chennai 600003, India
- Jaganathan Arjun
- Greater Chennai Corporation, Ripon Building, Chennai 600003, India
- Chethrapilly Purushothaman Girish Kumar
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Pragya D Yadav
- Indian Council of Medical Research—National Institute of Virology, Pune 411001, India
- Rima Sahay
- Indian Council of Medical Research—National Institute of Virology, Pune 411001, India
- Triparna Majumdar
- Indian Council of Medical Research—National Institute of Virology, Pune 411001, India
- Manisha Dudhmal
- Indian Council of Medical Research—National Institute of Virology, Pune 411001, India
- Azhagendran Sivalingam
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Sudha Rani Dhanapal
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Augustine Durai Samy
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Vijayaprabha Radhakrishnan
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Murali Mohan Muni Krishnaiah
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Suresh Arunachalam
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Punita Muni Krishna Gandhi
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Elavarasu Govindasamy
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Prabhakaran Chinnappan
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Dhana Priya Vadhani Sekar
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Prakash Marappan
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Ezhil Pounraj
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Parasuraman Ganeshkumar
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Murugesan Jagadeesan
- Greater Chennai Corporation, Ripon Building, Chennai 600003, India
- Manish Narnaware
- Greater Chennai Corporation, Ripon Building, Chennai 600003, India
- Gagandeep Singh Bedi
- Greater Chennai Corporation, Ripon Building, Chennai 600003, India
- Prabhdeep Kaur
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- Manoj Murhekar
- Indian Council of Medical Research—National Institute of Epidemiology, Tamil Nadu Housing Board, Chennai 600077, India
- DOI
- https://doi.org/10.3390/vaccines10060970
- Journal volume & issue
-
Vol. 10,
no. 6
p. 970
Abstract
We estimated the effectiveness of two doses of the ChAdOx1 nCoV-19 (Covishield) vaccine against any COVID-19 infection among individuals ≥45 years in Chennai, Tamil Nadu, India. A community-based cohort study was conducted from May to September 2021 in a selected geographic area in Chennai. The estimated sample size was 10,232. We enrolled 69,435 individuals, of which 21,793 were above 45 years. Two-dose coverage of Covishield in the 18+ and 45+ age group was 18% and 31%, respectively. Genomic analysis of 74 out of the 90 aliquots collected from the 303 COVID-19-positive individuals in the 45+ age group showed delta variants and their sub-lineages. The vaccine’s effectiveness against COVID-19 disease in the ≥45 age group was 61.3% (95% CI: 43.6–73.4) at least 2 weeks after receiving the second dose of Covishield. We demonstrated the effectiveness of two doses of the ChAdOx1 vaccine against the delta variant in the general population of Chennai. We recommend similar future studies considering emerging variants and newer vaccines. Two-dose vaccine coverage could be ensured to protect against COVID-19 infection.
Keywords
- COVID-19 vaccines
- vaccine effectiveness
- ChAdOx1 nCoV-19
- Covishield
- AZD 1222
- SARS-CoV-2 inactivated vaccines
